Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19585689 | 0.73 | MAP3K14 (0.33) | MAP3K14 | |
| SCHEMBL19606402 | 0.70 | — | — | |
| SCHEMBL20206747 | 0.65 | CRBN (0.33) | MAP3K14 | |
| SCHEMBL22930474 | 0.64 | — | — | |
| SCHEMBL22978934 | 0.62 | — | — | |
| SCHEMBL22978935 | 0.62 | — | — | |
| SCHEMBL9854581 | 0.62 | BLM (0.30) | — | |
| SCHEMBL21325306 | 0.61 | — | — | |
| SCHEMBL20207019 | 0.61 | — | — | |
| SCHEMBL12332514 | 0.60 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250121069-A1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2025-04-17 | — | — | US | disclosed |
| EP-4491236-A2 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Therapeutics, Inc. (US) | 2025-01-15 | — | — | EP | disclosed |
| EP-3454856-B1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS INC (US) | 2024-09-11 | — | — | EP | disclosed |
| US-12076405-B2 | Heterocyclic degronimers for target protein degradation | C4 THERAPEUTICS, INC. | 2024-09-03 | — | — | US | disclosed |
| US-20230014124-A1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2023-01-19 | — | — | US | disclosed |
| US-20230014124-A1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2023-01-19 | — | — | US | disclosed |
| US-10905768-B1 | Heterocyclic degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-10905768-B1 | Heterocyclic degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-10849982-B2 | C3-carbon linked glutarimide degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-10646575-B2 | Heterocyclic degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| US-10646575-B2 | Heterocyclic degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| EP-3454856-A1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Therapeutics, Inc. (US) | 2019-03-20 | — | — | EP | disclosed |
| US-20190076541-A1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Theraprutics, Inc. (US) | 2019-03-14 | — | — | US | disclosed |
| US-20190076541-A1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Theraprutics, Inc. (US) | 2019-03-14 | — | — | US | disclosed |
| US-20190076542-A1 | C3-CARBON LINKED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Theraprutics, Inc. (US) | 2019-03-14 | — | — | US | disclosed |
| WO-2017197055-A1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2017-11-16 | — | — | WO | disclosed |
| WO-2017197055-A1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2017-11-16 | — | — | WO | disclosed |
| WO-2017197056-A1 | BROMODOMAIN TARGETING DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2017-11-16 | — | — | WO | disclosed |
| WO-2017197056-A1 | BROMODOMAIN TARGETING DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2017-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10849982-B2 | C3-carbon linked glutarimide degronimers for target protein degradation | STUB1, UBE3C, UBE3A | MAP3K14 3670/4885 |
| US-20230014124-A1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | CRBN, MDM2, STUB1 | MAP3K14 1920/4885 |
| US-10646575-B2 | Heterocyclic degronimers for target protein degradation | CRBN, MDM2, STUB1 | MAP3K14 1920/4885 |
| US-12076405-B2 | Heterocyclic degronimers for target protein degradation | CRBN, MDM2, STUB1 | MAP3K14 1920/4885 |
| US-10905768-B1 | Heterocyclic degronimers for target protein degradation | CRBN, MDM2, STUB1 | MAP3K14 1920/4885 |
| US-20250121069-A1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | CRBN, MDM2, STUB1 | MAP3K14 1920/4885 |
| US-20190076541-A1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | CRBN, MDM2, STUB1 | MAP3K14 1920/4885 |
| US-20190076542-A1 | C3-CARBON LINKED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | STUB1, UBE3C, UBE3A | MAP3K14 3670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.